---
{"dg-publish":true,"permalink":"/entities/condition/huntington-s-disease/","tags":["condition","neurodegeneration","movement-disorder","genetic","trinucleotide-repeat"]}
---


# Huntington's Disease

## Overview
Huntington's Disease (HD) is a devastating inherited neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin (HTT) gene on chromosome 4. The mutant huntingtin protein causes selective neurodegeneration, particularly in the striatum, leading to a triad of motor, cognitive, and psychiatric symptoms.

## Genetics
- **Inheritance**: Autosomal dominant (50% risk to offspring)
- **CAG Repeats**:
  - Normal: <27 repeats
  - Intermediate: 27-35 (may expand in offspring)
  - Reduced penetrance: 36-39
  - Full penetrance: ≥40
- **Anticipation**: Earlier onset in successive generations (especially paternal)
- **Juvenile HD**: >60 repeats; onset before age 20

## Clinical Triad

### Motor Symptoms
- **Chorea**: Involuntary, irregular, flowing movements (early)
- **Dystonia**: Sustained abnormal postures (progresses)
- **Bradykinesia**: Slowness (late stage, "rigid" variant)
- **Gait instability and falls**
- **Dysphagia and dysarthria**

### Cognitive Symptoms
- Executive dysfunction (early)
- Processing speed decline
- Attention deficits
- Memory impairment (retrieval > encoding)
- Dementia (late stage)

### Psychiatric Symptoms
- Depression (most common; high suicide risk)
- Irritability and aggression
- Apathy
- Obsessive-compulsive behaviors
- Psychosis (less common)

## Pathophysiology
1. **Mutant Huntingtin Aggregation**: Toxic polyglutamine expansion
2. **Transcriptional Dysregulation**: Altered gene expression
3. **Mitochondrial Dysfunction**: Energy deficits
4. **Excitotoxicity**: Excessive glutamate signaling
5. **Striatal Degeneration**: Medium spiny neurons (D2 receptor) affected first

## Relationships

### Affected Brain Regions
- → [[entities/Organ/Striatum\|Striatum]] (organ) - *Primary degeneration site*
- → [[entities/Organ/Globus Pallidus\|Globus Pallidus]] (organ) - *Indirect pathway affected*
- → [[entities/Organ/Prefrontal Cortex\|Prefrontal Cortex]] (organ) - *Executive dysfunction*
- → [[entities/Organ/Substantia Nigra\|Substantia Nigra]] (organ) - *Late involvement*

### Biomarkers
- ← [[entities/biomarker/Neurofilament Light Chain\|Neurofilament Light Chain]] (biomarker) - *Elevated; tracks progression*
- ← [[Mutant Huntingtin CSF\|Mutant Huntingtin CSF]] (biomarker) - *Disease-specific*
- ← [[entities/Examination/MRI Volumetry\|MRI Volumetry]] (examination) - *Caudate atrophy*
- ← [[Genetic Testing\|Genetic Testing]] (examination) - *Definitive diagnosis*

### Symptomatic Treatments
- ← [[Tetrabenazine\|Tetrabenazine]] (drug) - *VMAT2 inhibitor for chorea*
- ← [[Deutetrabenazine\|Deutetrabenazine]] (drug) - *Improved tetrabenazine*
- ← [[Antipsychotics\|Antipsychotics]] (drug) - *Chorea and psychiatric symptoms*
- ← [[SSRIs\|SSRIs]] (drug) - *Depression management*

### Disease-Modifying Approaches (Investigational)
- ← [[Antisense Oligonucleotides\|Antisense Oligonucleotides]] (intervention) - *HTT lowering*
- ← [[Gene Therapy\|Gene Therapy]] (intervention) - *HTT silencing*

### Related Conditions
- → [[Chorea\|Chorea]] (condition) - *Primary motor manifestation*
- → [[Dementia\|Dementia]] (condition) - *Late-stage progression*

## Prognosis
- Typical onset: 30-50 years
- Disease duration: 15-20 years from onset
- Cause of death: Pneumonia, cardiovascular disease, suicide

## References
1. **Review**: Tabrizi, S.J., et al. (2022). "Huntington disease." *Nature Reviews Disease Primers*.
2. **Biomarkers**: Byrne, L.M., et al. (2017). "Neurofilament light protein in blood as a potential biomarker of HD." *Neurology*.
